Monograph
J07AG01 - Haemophilus Influenzae B, Purified Antigen Conjugated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hemophilus influenzae B, purified antigen conjugated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Haemophilus influenzae type b polysaccaride conjugated to tetanus carrier protein.
Therapeutic characteristics
The hemophilus influenza B vaccine is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b in children from 2 months through 5 years of age. It is administered by intramuscular injections, in infants usually according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hemophilus influenza B vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Act-Hib.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Act-Hib 
Act-HIB · Hiberix 
act-hib · Hiberix 
Hiberix vaccine · HibTITER vaccine 
Act-HIB 
Act-HiB 
Act-HIB 
Act-Hib 
Act-Hib
© NAPOS 2025